What Is AOD 9604?
AOD 9604 peptide is one of the more extensively researched compounds in lipolysis peptide and fat metabolism research circles. It is a synthetic analog of human growth hormone (HGH), originating from the modification of the growth hormone’s last 16 amino acids at positions 176 to 191. Also known as GH Fragment 176-191, AOD 9604 incorporates a tyrosine residue at the N-terminus that researchers suggest may contribute to the peptide’s stability in laboratory settings.
What makes this fat metabolism peptide particularly interesting from a research standpoint is its proposed selectivity. AOD 9604 is hypothesized to potentially induce lipolysis without significant impacts on insulin and IGF-1 levels in laboratory models, potentially moderating risks associated with glucose intolerance in these experimental settings. The structural similarity between AOD 9604 and HGH also appears to minimize the likelihood of antibody formation in laboratory models, making it a useful research tool for studying isolated fat metabolism dynamics. Research has since revealed a research profile that extends well beyond lipolysis alone, with laboratory investigations now exploring its interactions across cellular regeneration and cancer cell biology.
Proposed Mechanism in Laboratory Models
At the foundation of this peptide research is its proposed mechanism involving lipolysis and the inhibition of lipogenesis in laboratory models. Researchers have proposed that AOD 9604 may operate by potentially eliciting fat breakdown while impeding the formation of new fat stores in laboratory settings. Notably, these interactions are speculated to be achieved through oxidative pathways and may occur independently of the HGH receptor in these models.
Research suggested that this lipolysis peptide may potentially facilitate the release of fat from adipose tissue while moderating the accumulation of new fat deposits in laboratory models, without appearing to alter caloric intake or appetite or adversely affect insulin sensitivity in these experimental settings. These proposed properties have positioned AOD 9604 as a particularly active subject of fat metabolism peptide research in controlled laboratory environments.
AOD 9604 and Lipolysis Research
Early laboratory investigations into the fat metabolism potential of AOD 9604 peptide involved studies conducted on obese mice over a period of 14 days. Research by Heffernan et al. reported a significant decrease in body weight and adipose tissue accumulation in these laboratory models following peptide exposure. Concurrently, an elevation in the levels of key lipolytic receptors, specifically beta-3-adrenergic receptors within adipocytes, was observed in these models. Researchers proposed a direct correlation between the reduction in adiposity and the augmented expression of these receptors in laboratory settings.
To further explore whether AOD 9604’s lipolytic interactions depend solely on enhanced receptor expression, investigations were also conducted using mice with genetically ablated lipolytic receptors in laboratory settings. Subsequent analyses suggested that AOD 9604 peptide may exert lipolytic interactions through mechanisms involving heightened energy expenditure and enhanced fat oxidation in these models, suggesting multiple potential pathways for this lipolysis peptide’s fat metabolism research interactions.
A subsequent study in 2000 evaluated AOD 9604 peptide in obese Zucker rats through daily exposure over 19 consecutive days. Research by Ng et al. indicated that the peptide reduced over 50% of body weight gain in these laboratory models compared to controls, with heightened lipolytic activity observed within the adipose tissues of exposed rats, alongside an absence of notable disruptions in insulin sensitivity in these experimental settings.
AOD 9604 and Cellular Regeneration Research
Beyond its fat metabolism research profile, AOD 9604 has also been studied for its potential interactions with cellular regeneration processes in laboratory models. Research by Kwon and Park involving 32 white rabbits divided into four groups explored the extent of cartilage degeneration following exposure to a placebo, AOD 9604 alone, hyaluronic acid alone, or a combination of AOD 9604 and hyaluronic acid over a period of 4 to 7 weeks. Findings indicated that rabbits exposed to the combination of AOD 9604 and hyaluronic acid appeared to exhibit the least degeneration in cartilage tissue in these laboratory models.
Researchers proposed that the mechanisms underlying these regenerative interactions may involve the modulation of cellular differentiation processes and the synthesis of proteins important for tissue repair in laboratory settings. In vitro investigations suggested that AOD 9604 may promote the differentiation of adipose-derived mesenchymal stem cells into osteogenic lineages in laboratory models, potentially supporting bone regeneration research. Experiments conducted on isolated bovine chondrocytes also revealed an apparent upregulation in the production of proteoglycans and collagen in these laboratory settings, fundamental components of the extracellular matrix considered essential for cartilage integrity. Additionally, data suggested that AOD 9604 may stimulate the differentiation of myoblasts into mature muscle cells in laboratory models, highlighting a possible role in muscle tissue repair research.
AOD 9604 and Cancer Cell Research
Rounding out this lipolysis peptide’s expanding research profile, AOD 9604 has also been explored in laboratory contexts involving cancer cell biology. Research by Habibullah et al. investigated whether AOD 9604 may potentially support the interactions of certain chemotherapeutic compounds in laboratory cancer cell models. The study employed chitosan nanoparticles as carriers for both a chemotherapy compound and AOD 9604 peptide, hypothesizing that AOD 9604 may potentially facilitate the binding of the compound to multiple protein targets within breast cancer cells in laboratory settings.
Researchers reported that dual-loaded chitosan nanoparticles demonstrated greater anti-proliferative activity against a breast cancer cell line compared to doxorubicin-loaded chitosan alone in these laboratory models. These findings have suggested the potential of AOD 9604 in laboratory research exploring interactions between peptides and conventional anticancer research compounds, while researchers have been careful to frame all findings as preliminary laboratory observations requiring substantial further investigation before any broader conclusions can be drawn.
References
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001;142(12):5182–9.
- Moré M, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3.
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–8.
- Medical and Life Sciences. Obesity drug codenamed AOD 9604 highly successful in trials. 2004.
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45.
- Habibullah MM, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022;16:1963–1974.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
